Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved UK pharma major GSK’s (LSE: GSK) Blenrep (belantamab ...

In separate live virtual events, Sarah A. Holstein, MD, PhD, and Shashank Cingam, MD, discuss options for a patient with relapsed/refractory multiple myeloma and the use of chimeric antigen receptor ...

GSK plc has received approval for Blenrep combinations from Japan's Ministry of Health, Labour and Welfare (MHLW) for the ...

The dose escalation for multiple myeloma is complete ... Management will participate in the Jefferies Global Healthcare Conference taking place from June 3 – June 5, 2025 in New York, New ...

Cambridge, UK-based CellCentric today announced the completion of a $120 million Series C funding round. The clinical-stage ...

The final ALCYONE analysis with 86.7-month follow-up shows daratumumab-VMP significantly improved overall survival in ...

“There is no cure for multiple myeloma. We believe there remains an unmet medical need for CAR-T therapies that are efficacious, safe, and accessible. Anito-cel has the unique potential to ...

HealthDay News — Annual whole-body, low-dose computed tomography (WBLDCT) can improve the management of smoldering multiple myeloma (SMM), according to a study published online March 25 in the Journal ...

It joins a number of other BCMA-directed therapies for multiple myeloma, including GSK's first-to-market antibody-drug conjugate Blenrep (belantamab mafodotin), Bristol-Myers Squibb/bluebird bio's ...